ALEC Key Statistics, Chart & Performance
The current stock price of ALEC is 1.45 USD. In the past month the price increased by 13.28%. In the past year, price decreased by -18.54%.
ALEC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ALEC
Company Profile
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 156 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Company Info
ALECTOR INC
131 Oyster Point Blvd., Suite 600
South San Francisco CALIFORNIA 94080 US
CEO: Arnon Rosenthal
Employees: 238
Phone: 14152315660
ALECTOR INC / ALEC FAQ
What does ALECTOR INC do?
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 156 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
What is the current price of ALEC stock?
The current stock price of ALEC is 1.45 USD. The price increased by 2.84% in the last trading session.
Does ALEC stock pay dividends?
ALEC does not pay a dividend.
What is the ChartMill rating of ALECTOR INC stock?
ALEC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ex-dividend date for ALEC stock?
The next ex-dividend date for ALECTOR INC (ALEC) is November 4, 2022.
How many employees does ALECTOR INC have?
ALECTOR INC (ALEC) currently has 238 employees.
What is ALECTOR INC worth?
ALECTOR INC (ALEC) has a market capitalization of 158.27M USD. This makes ALEC a Micro Cap stock.
ALEC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALEC. When comparing the yearly performance of all stocks, ALEC is a bad performer in the overall market: 90.91% of all stocks are doing better.
ALEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALEC. Both the profitability and financial health of ALEC have multiple concerns.
ALEC Financial Highlights
Over the last trailing twelve months ALEC reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 37.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.13% | ||
| ROE | -186.68% | ||
| Debt/Equity | 0.17 |
ALEC Forecast & Estimates
14 analysts have analysed ALEC and the average price target is 2.09 USD. This implies a price increase of 44.21% is expected in the next year compared to the current price of 1.45.
For the next year, analysts expect an EPS growth of -21.55% and a revenue growth -73.33% for ALEC